Effects of ABVD chemotherapy on ovarian function: epidemiology, hormonal dosages and ultrasound morphologic analyses in 270 patients with Hodgkin's disease.
Anti-Mullerian hormone
Hodgkin’s lymphoma
early menopause
fertility preservation
ovarian failure
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
10
2022
accepted:
27
03
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
Classical Hodgkin Lymphoma (HL) is a lymphoproliferative disease typically diagnosed in the young. The excellent results obtained with current treatment lead to long survival with age-related complications affecting patients' survival and quality of life. One issue affecting HL patients is infertility. This problem can be easily overcome in males with seminal liquid cryopreservation, however, in females it is more complex either in terms of the quality of the cryopreserved material or the patients' age at diagnosis. Moreover, not all chemo- or radio-therapies have the same negative impact on fertility.The main objectives of this study was to collect epidemiological information on HL patients involved in fertility preservation counseling and to analyze the impact of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine), the standard treatment for HL, on ovarian function, hormonal levels and ovarian and uterine tissue morphologies. Patterns of fertility preservation were also reported. Data were obtained from 270 female patients at HL onset who were interested in fertility counseling prior to therapy initiation. Each patient was assessed at HL diagnosis for levels of Anti-Mullerian Hormone (AMH), Follicle Stimulating Hormone (FSH), and 17β-oestradiol (17β-oe), with additional assessments at 6 and 12 months after chemotherapy. Patients were evaluated with ultrasound scans to study the number of ovarian follicles and the degree of uterine thickness at the same timepoints. The average patient AMH level showed a statistically significant reduction at 6 months after chemotherapy (p=0.05) and by the 12 month time point returned to near pre-chemotherapy values. FSH and 17β-oe levels did not significantly vary throughout the study period. ABVD chemotherapy was associated with a significant reduction of both ovarian follicles and endometrial thickness at the 6 month time point followed by a recovery at the 12 time point in both ovaries. Different results were observed when patients changed treatment to a more intensive one. Based on the results from the hormonal measurements and the follicle echography, it appears that the toxic effect of ABVD on fertility is transient, whereas, in contrast, more intensive therapies may potentially be more harmful and long-lasting.
Identifiants
pubmed: 37152067
doi: 10.3389/fonc.2023.1059393
pmc: PMC10160490
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1059393Informations de copyright
Copyright © 2023 Ciccarone, Cavaceppi, Tesei, Brunetti, Pulsoni, Annibali, Gasparoli, Battistini, Hohaus, Pelliccia, Tafuri, Cox, Cantonetti, Rigacci and Abruzzese.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Treat Rev. 2019 Jan;72:65-77
pubmed: 30530271
Eur J Cancer. 2013 Nov;49(16):3404-11
pubmed: 23968732
J Clin Oncol. 2013 Jan 10;31(2):231-9
pubmed: 23150709
N Engl J Med. 2017 Oct 26;377(17):1657-1665
pubmed: 29069558
JAMA. 2011 Jul 20;306(3):269-76
pubmed: 21771987
Reprod Biomed Online. 2010 Feb;20(2):280-5
pubmed: 20113967
Hematol Rep. 2022 Mar 28;14(2):85-94
pubmed: 35466177
Hematology. 2022 Dec;27(1):181-186
pubmed: 35068389
Hematol Oncol. 2013 Jun;31(2):72-8
pubmed: 23027689
Cancers (Basel). 2021 Jun 09;13(12):
pubmed: 34207634
Curr Opin Obstet Gynecol. 2016 Aug;28(4):223-9
pubmed: 27253235
Br J Cancer. 2013 Jun 11;108(11):2399-406
pubmed: 23652303
Lancet. 2014 Oct 4;384(9950):1302-10
pubmed: 25283571
J Clin Oncol. 2016 Aug 1;34(22):2568-74
pubmed: 27217453
Haematologica. 2002 May;87(5):ELT24
pubmed: 12010684
BMC Med. 2016 Jan 04;14:1
pubmed: 26728489
Best Pract Res Clin Obstet Gynaecol. 2022 May;81:119-133
pubmed: 34887172
J Clin Oncol. 2007 Aug 20;25(24):3746-52
pubmed: 17646666
J Assist Reprod Genet. 2008 Nov-Dec;25(11-12):535-8
pubmed: 19015974
Eur J Cancer. 2017 Jan;71:25-33
pubmed: 27940355
Eur J Cancer Care (Engl). 2020 Jan;29(1):e13174
pubmed: 31571303
Ann Oncol. 2010 Oct;21(10):2052-2060
pubmed: 20305034
Haematologica. 2019 Aug;104(8):e360-e363
pubmed: 30765476
Hum Reprod. 2021 Sep 18;36(10):2743-2752
pubmed: 34417822
J Clin Oncol. 2021 Nov 1;39(31):3463-3472
pubmed: 34170749
J Assist Reprod Genet. 2020 Jul;37(7):1755-1761
pubmed: 32488563
J Assist Reprod Genet. 2012 Jun;29(6):479-87
pubmed: 22614159
Fertil Steril. 2019 Dec;112(6):1022-1033
pubmed: 31843073
Cancer. 2015 Nov 15;121(22):3938-47
pubmed: 26264701
Cancer Treat Rev. 2014 Jun;40(5):675-83
pubmed: 24360817
Lancet Oncol. 2018 Oct;19(10):1328-1337
pubmed: 30220622
Haematologica. 2006 Apr;91(4):475-81
pubmed: 16585014
Obstet Gynecol Surv. 2020 Nov;75(11):683-691
pubmed: 33252698
Fertil Steril. 2020 Oct;114(4):725-738
pubmed: 33040981
J Assist Reprod Genet. 2012 Jun;29(6):473-7
pubmed: 22562284
Hematol Oncol. 2007 Mar;25(1):11-5
pubmed: 17036376
Front Oncol. 2021 Jun 03;11:690320
pubmed: 34150661
Br J Cancer. 2007 May 7;96(9):1442-9
pubmed: 17406362
Curr Opin Endocrinol Diabetes Obes. 2016 Dec;23(6):465-469
pubmed: 27685935
Maturitas. 2015 Mar;80(3):245-50
pubmed: 25596814
Reprod Biomed Online. 2018 May;36(5):508-523
pubmed: 29503212
J Assist Reprod Genet. 2012 Jun;29(6):465-8
pubmed: 22648282
Haematologica. 2000 Oct;85(10):1032-9
pubmed: 11025593
Hum Reprod Update. 2014 Sep-Oct;20(5):688-701
pubmed: 24821925
Ann Oncol. 2012 Jul;23(7):1818-25
pubmed: 22228451